Acetaminophen: Old drug, new warnings

ABSTRACT

The US Food and Drug Administration (FDA), concerned about the incidence of acute liver failure due to acetaminophen (Tylenol) overdose, has mandated new labeling on acetaminophen packaging. It is also considering (but has not enacted) reducing the maximum daily dose from 4 g (possibly to 3,250 mg), banning acetaminophen-narcotic combination products, and changing the current maximum single dose of 1 g to prescription status, making 650 mg the highest recommended nonprescription dose. We review the epidemiology, toxicology, and management of acetaminophen overdose and steps the FDA and physicians can take to prevent it.

KEY POINTS

Acetaminophen is the leading cause of acute liver failure in the United States, and nearly half of acetaminophen-associated cases are due to unintentional overdose.

In many cases of unintentional overdose, patients took more than one acetaminophen-containing product and did not know that both products contained this drug.

Prescribers need to inform all patients, especially vulnerable ones (eg, those taking enzyme-inducing drugs, those who chronically use alcohol, and those who are malnourished) of the risks associated with acetaminophen.

Although no consensus has been reached on what is a safe dose in patients with liver disease, 4 g/day is too much: a total daily dose of no more than 2 g is recommended to decrease the risk of toxicity in these patients.

Editor’s note: Portions of this article are based on an article previously published in an internal Cleveland Clinic publication, Pharmacotherapy Update. The version here has been revised, updated, and peer-reviewed.

ACETAMINOPHEN (Tylenol, also known as paracetamol, N-acetyl-p-aminophenol, and APAP) is a popular antipyretic and analgesic found in many over-the-counter and prescription products, including cough-and-cold remedies and narcotic pain relievers (TABLE 1).1

This drug is generally considered safe, but high doses can be toxic. The number of overdoses is worrisome. In 2006 alone, the American Association of Poison Control Centers implicated acetaminophen in nearly 140,000 poisoning cases, in which more than 100 patients died.2 It is responsible for more emergency room visits than any other drug on the market.

According to a position statement from the American Association for the Study of Liver Diseases (AASLD),3 the incidence of acetaminophen-related liver toxicity has been steadily increasing over the past decade, and this drug is now the most common cause of acute liver failure.

MANY OVERDOSES ARE UNINTENTIONAL

Cases of acetaminophen-related liver toxicity can be categorized as either intentional (ie, due to a suicide attempt) or unintentional (ie, due to multiple therapeutic but excessive doses over a period of time, usually more than 3 days).

Up to 50% of cases are unintentional. Bower et al4 reviewed cases of acute liver failure that occurred in the Atlanta, GA, area between November 2000 and October 2004. Ac-
Acetaminophen was the most common cause in adult patients. Of greater concern is that 61% of the acetaminophen-related cases were due to unintentional overdose. According to the Institute for Safe Medication Practices,5 one hospital (not named) reported that an average of one patient per day was given more than the recommended maximum daily acetaminophen dose of 4 g while in the hospital.

Many patients take more than one acetaminophen product

Unintentional overdoses or “therapeutic misadventures” are most often due to taking multiple products that contain acetaminophen, taking acetaminophen-narcotic combinations, and impulsive behavior involving a lack of understanding of possible injury in consuming multiple acetaminophen-containing products.3

In the US Food and Drug Administration (FDA) MedWatch Database, in 307 cases of unintentional acetaminophen overdose between 1998 and 2001, 25% of patients had been taking more than one acetaminophen-containing product.5

Larson et al6 found that one-third of patients who had had an unintentional acetaminophen overdose were taking an acetaminophen-narcotic combination in addition to another acetaminophen-containing product.

Many consumers don’t know they are taking acetaminophen

Many consumers don’t know that some of the drugs they take contain acetaminophen. This may be because many drug labels contain abbreviations for acetaminophen such as “APAP” or have inconsistent formatting that makes it difficult to determine if the product contains acetaminophen.

Others may not be aware of the total maximum recommended daily dose or may not be able to calculate the total daily intake from the information on the label. The problem is not only with over-the-counter products. For example, if a physician prescribes one or two tablets of hydrocodone/acetaminophen (Vicodin) 5 mg/500 mg every 4 to 6 hours, a patient could easily exceed the recommended maximum daily dose of 4 g of acetaminophen.

Toxicity can occur even at therapeutic doses

Acetaminophen hepatotoxicity can also occur even with therapeutic doses in certain conditions. Risk factors:

- Chronic alcohol use (ie, more than three drinks per day)
- Malnutrition
- Concurrent use of drugs that induce cytochrome P450 (CYP450) enzymes (more on this below).6

FIRST USED IN 1893

Acetaminophen was first used in medicine in 1893, and it became widely used after 1949, when it was found to be a less-toxic metabolite of two parent compounds, acetanilide and phenacetin.1

Acetaminophen is an effective antipyretic and analgesic, but its anti-inflammatory properties are minimal, especially compared with nonsteroidal anti-inflammatory drugs
Acetaminophen is generally safe, but excessive doses and conditions that overwhelm its normal metabolic pathways can lead to liver damage.

Glucuronidation, sulfation, and subsequent renal excretion normally remove 90% of a therapeutic dose, but these pathways can become saturated after an acetaminophen overdose.

**Cytochrome P450 metabolism** produces a toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI). This pathway produces more NAPQI after higher doses, or when the relevant cytochrome P450 (CYP) enzymes are induced by other drugs or chronic alcohol consumption.

NAPQI is toxic to the liver. Conjugation of sulfhydryl groups of glutathione normally detoxifies NAPQI. However, glutathione can become depleted after large doses of acetaminophen or in malnourished people, allowing this toxic metabolite to accumulate.

**INDICATIONS AND DOSAGE**

Acetaminophen is indicated for mild to moderate pain or fever, including the pain of osteoarthritis. It is not recommended for chronic inflammatory conditions such as rheumatoid arthritis, since it lacks anti-inflammatory properties.

In adults and in children over age 12, the usual dosage is 325 to 650 mg orally or rectally every 4 to 6 hours, or 1,000 mg three to four times daily.

The current package label recommends that the total daily dose not exceed 4 g in most adults. Lower maximum daily doses (eg, 2 g) are recommended in patients who may be at higher risk of hepatotoxicity, such as those who drink heavily, are malnourished, or take enzyme-inducing drugs. Tylenol products currently include an alcohol warning, advising those who consume three or more alcoholic drinks a day to ask their doctor if they should take acetaminophen.

In children up to 12 years of age, the recommended dosage is 10 to 15 mg/kg orally or rectally every 4 to 6 hours. The maximum dosing for children in this age group should not exceed five doses (or 50 to 75 mg/kg) in 24 hours. In children under age 2 or weighing less than 11 kg, acetaminophen should only be used under the direction of a physician.

**MOST ACETAMINOPHEN IS CONJUGATED AND THEN EXCRETED IN THE URINE**

Acetaminophen usually has excellent bioavailability (up to 98%), but the exact amount absorbed varies, depending on the dosage form and concomitant use of other drugs.
At therapeutic doses, the elimination half-life is about 2 hours. Peak plasma concentrations are reached 30 to 60 minutes after the dose is taken, but taking acetaminophen with opioids, anticholinergic drugs, or even food may delay the time to peak concentration by delaying gastric emptying.

**NAPQI is a toxic metabolite**

Most of the acetaminophen in the blood undergoes conjugation in the liver with glucuronic acid (40%–67%) and sulfates (20%–46%). The conjugated metabolites, as well as small amounts that have been hydroxylated and deacetylated, are excreted in the urine (FIGURE 1).

Under normal circumstances, a small amount of acetaminophen undergoes hepatic metabolism by a different pathway, ie, by CYP450 enzymes, primarily CYP2E1 and to a lesser extent CYP1A2, CYP2A6, and CYP3A4, forming a toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI). Then, the sulfhydryl groups of glutathione convert NAPQI into harmless metabolites that are excreted in the urine.

**Well tolerated and relatively safe**

At recommended doses, acetaminophen is well tolerated, and it is considered relatively safe when used according to labeling instructions.

Rarely, patients experience an erythematous or urticarial rash or other allergic complications.

However, acetaminophen is a dose-dependent hepatotoxin, and excessive doses (intentional or unintentional) may lead to acute liver failure. In addition, even in therapeutic doses, acetaminophen may still cause transient liver enzyme elevations and possibly hepatotoxicity, particularly in people who are malnourished or alcoholic or are taking certain CYP450-inducing drugs.

Patients who are malnourished or fasting are thought to be at greater risk of acetaminophen hepatotoxicity because they may be deficient in glutathione at baseline. In addition, even at lower-than-therapeutic doses, induction of CYP450 enzymes by drugs or chronic alcohol consumption may lead to an increase in the formation of NAPQI, increasing the risk of hepatotoxicity. Examples of drugs that induce CYP450 enzymes to produce more NAPQI include the anticonvulsants phenytoin (Dilantin) and phenobarbital.

**Clinical Presentation of Acetaminophen Overdose**

The diagnosis of acetaminophen overdose is often established by a thorough history. The pertinent information may be difficult to obtain, however, because the patient may be confused or stuporous at presentation, may not know that the over-the-counter products he or she has been taking contain acetaminophen, or may be embarrassed about taking too much acetaminophen.

**In acute intentional overdose, signs may not be apparent immediately**

The symptoms of toxicity may not be apparent immediately after ingestion of an acute overdose of acetaminophen, but early recognition and treatment can prevent more severe liver damage, decreasing morbidity and the risk of death.
Phase 1 of an acetaminophen overdose begins shortly after ingestion and can last for 12 to 24 hours. Patients may have signs of gastrointestinal upset, nausea, vomiting, anorexia, diaphoresis, and pallor. Although the signs and symptoms show a consistent pattern and are more pronounced after larger acute overdoses, they are not diagnostic or specific.

Phase 2 (up to 48 hours after ingestion). Patients may begin to feel better during this phase. However, the hepatic enzyme levels, the prothrombin time (PT), and the international normalized ratio (INR) may continue to rise, and right upper quadrant pain may develop. Additionally, other laboratory results may be abnormal, and renal insufficiency can occur due to acetaminophen-induced renal tubular necrosis.6 Most patients receive the antidote, acetylcysteine (Mycymyst, Acetadote) before or during this phase, and consequently, liver function gradually returns to normal.

Phase 3, if reached, may be marked by severe hepatic necrosis, typically 3 to 5 days after ingestion. Symptoms during this phase range from less severe (eg, nausea and general malaise) to more severe (eg, confusion and stupor). Also, at this time, liver enzyme levels can be as high as 10,000 IU/L or even higher, and lactic acidosis and coagulopathy may worsen. If death should occur, it is most likely from complications associated with fulminant hepatic failure, including cerebral edema, multiorgan-system failure, or sepsis.6

Phase 4. Patients who recover generally have complete recovery of liver function with no long-term sequelae.

In unintentional overdoses, patients may have low drug levels
Many patients who present with unintentional acetaminophen toxicity have been taking the drug or products that contain the drug over several days to treat an acute or chronic medical condition. They often have low or undetectable serum acetaminophen levels after 2 to 3 days of nonspecific symptoms.12

MANAGING ACETAMINOPHEN OVERDOSE

Measuring serum acetaminophen levels may be useful in cases of single, acute overdoses if the time since ingestion is known. The Rumack-Matthew nomogram (FIGURE 2), used in cases of acute acetaminophen overdose, predicts the probability of hepatotoxicity on the basis of plasma levels and time after ingestion.13–15

Unintentional overdoses occur over a more prolonged period, and therefore the nomogram is not useful in this situation.

Acetylcysteine is the antidote
Acetylcysteine is the antidote for acetaminophen toxicity and should be given within 8 hours of ingestion for maximal protection against hepatic injury in patients whose serum acetaminophen levels are above the “possible” toxicity line on the nomogram.15 If acetaminophen toxicity is suspected, the nomogram should be used to determine the possibility of hepatotoxicity. If the serum acetaminophen level is above the white zone on the nomogram, the patient should be treated with acetylcysteine. If the level is within the gray zone, the patient may be monitored closely for signs of hepatic toxicity. If the level is below the green zone, no treatment is necessary.

In children, the dose of acetylcysteine is calculated based on body weight. The recommended dose for children is 140 mg/kg up to a maximum of 15 g. The treatment should be started as soon as possible after ingestion, but no later than 16 hours after ingestion.

In patients with severe hepatic injury, hemodialysis may be necessary to remove the drug from the body. Hemoperfusion is an alternative to dialysis and may be more effective in removing the drug from the body. However, this procedure is expensive and not widely available.

In patients with renal failure, the half-life of acetaminophen may be prolonged, and the dose of acetylcysteine may need to be increased. In patients with hepatic failure, the dose of acetylcysteine may need to be reduced.

In patients with hepatic and renal failure, the dose of acetylcysteine may need to be reduced.

In patients with hepatic and renal failure, the dose of acetylcysteine may need to be reduced.

In patients with hepatic and renal failure, the dose of acetylcysteine may need to be reduced.

In patients with hepatic and renal failure, the dose of acetylcysteine may need to be reduced.
Acetaminophen overdose is suspected but the time elapsed since ingestion cannot be determined, acetylcysteine should be given immediately regardless of the quantity of acetaminophen ingested.16 In cases of unintentional overdose, it is often given at the discretion of the physician. Acetylcysteine limits the toxicity of acetaminophen by increasing glutathione stores, binding with NAPQI as a substitute for glutathione, and enhancing sulfate conjugation.6 It may further limit acetaminophen toxicity by nonspecific mechanisms including anti-inflammatory, antioxidant, inotropic, and vasodilating effects.6 In addition, it may prevent further hepatic damage in any patient thought to have acetaminophen-related liver toxicity even beyond the first 12 hours of an overdose.1

Acetylcysteine is available in an oral (Mucomyst) and an intravenous (Acetadote) formulation, which are similar in efficacy. Because many patients find the taste of the oral solution unpleasant and difficult to tolerate, it should be diluted in a 1:3 ratio with cola, orange juice, or other drink to mask its flavor. This mixture should be used within 1 hour of preparation.

Anaphylactoid reactions have occurred in patients receiving intravenous acetylcysteine for acetaminophen overdose soon after the infusion was started, most commonly during the loading dose. The frequency of infusion-related reactions has been reported to be 0.2% to 20.8%.15 The recommended dosage for intravenous acetylcysteine is a loading dose of 150 mg/kg given over 60 minutes, followed by a second dose of 50 mg/kg given over 4 hours, and finally a third dose of 100 mg/kg given over 16 hours.15 For oral acetylcysteine, the loading dose is 140 mg/kg followed by 70 mg/kg every 4 hours for 17 additional doses.17

Other measures
Activated charcoal can be used if the patient presents within 1 to 2 hours after taking acetaminophen. However, the rapid gastrointestinal absorption of acetaminophen makes this treatment ineffective in most cases.9

Liver transplantation. In patients with acute liver failure and a poor prognosis, early referral to a liver transplant center is essential. The King’s College criteria (Table 2),18 a widely used prognostic model in patients with acute liver failure, are used to predict the need for liver transplantation. They are based on the arterial pH, the PT and INR, the severity of encephalopathy, and the serum creatinine concentration.

TABLE 2
King’s College criteria for poor prognosis in acute liver failure

| In acetaminophen-induced acute liver failure |
| Arterial pH < 7.3 |
| Or all of the following: |
| Grade III or IV encephalopathy |
| Prothrombin time > 100 seconds |
| Serum creatinine > 3.4 mg/dL |

| In acute liver failure from other causes |
| Prothrombin time > 100 seconds |
| Or three of the following: |
| Age < 10 years or > 40 years |
| Non-A, non-B hepatitis, halothane-induced hepatitis, idiosyncratic drug reactions |
| More than 7 days of jaundice before the onset of encephalopathy |
| Prothrombin time > 50 seconds |
| Serum bilirubin > 18 mg/dL |

unknown. The median amount ingested was 13.2 g/day (range 2.6–75 g), and 99 (83%) of the 120 patients took more than 4 g/day.

The patients with acetaminophen-related acute liver toxicity differed from those with other causes of acute liver failure such as idiosyncratic drug reactions or indeterminate causes. The acetaminophen group had a shorter duration of disease and higher serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine than those with acute liver failure from other causes. They also had lower bilirubin levels and a lower arterial pH.

Rates of liver transplantation were 6% in the acetaminophen group, 53% in the group with other drug-induced liver toxicity, 51% in the indeterminate group, and 36% in the remaining groups. Of the acetaminophen group, 47% met the criteria for transplantation, but only 57% of those eligible were listed for transplantation. Those excluded from the transplant list had medical contraindications or were excluded for psychosocial reasons. The short-term transplant-free survival rate was 68% in the acetaminophen group.

Overall, 11% of the patients died, including 28% of the acetaminophen group. The authors concluded that most cases of liver injury in the United States are due to medications and may be preventable.

Larson et al., as part of the Acute Liver Failure Study Group, examined the incidence, risk factors, and outcomes of acetaminophen-induced acute liver failure at 22 tertiary care centers in the United States over a 6-year period. Of the 662 patients in the study, 302 had acetaminophen-related toxicity and 275 were included in the final analysis; some of them had been included in the study by Ostapowicz et al. During the study period, the number of cases of acute liver toxicity related to acetaminophen increased from 28% to 51%.

Of the cases enrolled in the study, 56% met the criteria for potentially toxic acetaminophen ingestion. Of those who met the criteria, 77% had detectable acetaminophen levels in their serum, and 91% had ALT levels higher than 1,000 IU/L. The time between ingestion and symptom onset ranged from 1 to 32 days, and the median dose was 24 g (range 1.2–180 g).

Of the overdose cases, 48% were unintentional, 44% were intentional, and the remaining 8% had no definable reason. Of the patients in the unintentional-overdose group, 38% were using more than one acetaminophen-containing product and 63% were taking combination products containing narcotics. Overall, 44% of patients reported using narcotic-acetaminophen combination products. The unintentional-overdose group had lower serum acetaminophen levels than the intentional-overdose group, but they were more likely to present with severe hepatic encephalopathy.

The number of patients with an unintentional overdose was worrisome. Furthermore, one-third of the patients who were receiving an acetaminophen-narcotic combination product were taking an additional acetaminophen-containing product. The authors concluded that unintentional overdose is the leading cause of acetaminophen-related hepatotoxicity, and efforts to limit the over-the-counter package size and to restrict prescriptions of acetaminophen-narcotic combinations may be necessary to decrease the incidence of this preventable cause of acute liver failure.

Findings in children

Squires et al. and the Pediatric Acute Liver Failure Study Group examined the pathogenesis, treatment, and outcome of acute liver failure in children (any age from birth to 18 years) with no previous evidence of chronic liver disease, evidence of acute liver injury, or hepatic-based coagulopathy. From December 1999 to December 2004, 348 patients were enrolled.

Fourteen percent of the cases were due to acetaminophen. The median dose of acetaminophen ingested was 183 mg/kg. Most of these patients were white and female, and 96% were over age 3. Hepatic encephalopathy was more common in the non-acetaminophen groups than in the acetaminophen group, although this is often difficult to assess in infants and children. Children with acetaminophen toxicity had the highest rate of spontaneous recovery: 45 (94%) of 48 recovered.

Although there are fewer acetaminophen-related cases of acute liver failure in children than in adults, the use of acetaminophen in
Acetaminophen

children is still worrisome. The authors concluded that if they do not have hepatic encephalopathy, children with acetaminophen-induced liver toxicity have an excellent prognosis.

THE FDA LOOKS AT THE PROBLEM

Why overdoses occur
A recent FDA report cited the following reasons for acetaminophen overdose:

- Some patients may experience liver injury at doses only slightly above the recommended 4-g daily limit.
- Some patients may be more prone to liver injury from acetaminophen.
- The symptoms associated with liver injury due to acetaminophen can be nonspecific and tend to evolve over several days.
- Many acetaminophen-containing products are available, including over-the-counter and prescription drugs with many different strengths and indications.
- Consumers are unaware of the risk of liver toxicity with acetaminophen.
- Prescription products are not always clearly labeled with acetaminophen as an ingredient.
- Pediatric dosage forms are available in many different concentrations.

New package labeling
In view of this information, the FDA has mandated new labeling for acetaminophen-containing products (Table 3).

The United Kingdom Acted in 1998
In response to a rising number of analgesic-related deaths, the United Kingdom enacted legislation in 1998 to limit the package size available to consumers. Packages sold in general stores can contain no more than 16 capsules, while those sold in pharmacies can contain 24. Blister packs were also introduced to make it harder for people to impulsively take handfuls of tablets.

Two studies since then both found that the number of deaths related to paracetamol (as acetaminophen is known in the United Kingdom) had fallen since the legislation was implemented. Greene et al found that patients who ingested potentially toxic doses of paracetamol had obtained the drug “in a manner contravening the 1998 legislation.” In other words, shops in London were not obeying the law.

### TABLE 3
Updated labeling requirements for over-the-counter products containing acetaminophen

- Alcohol warning is included as part of the liver warning, instead of the separate alcohol warning previously required.
- Warning included information on the potential for severe liver damage associated with exceeding the maximum daily dose or consuming three or more alcohol-containing drinks per day while taking acetaminophen.
- The liver warning is required directly on the container labels in addition to the carton or outer container.
- The ingredient name (ie, acetaminophen) is highlighted or in bold type and in a prominent print size on the package’s principal display panel.
- The statement “See new warning information” is highlighted or in bold type and in a prominent print size on the principal display panel.
- The label must contain a warning to avoid concomitant use of other acetaminophen-containing products and instructions to speak with a physician before taking acetaminophen if the user has liver disease or is using warfarin.

SCHILLING AND COLLEAGUES

■ SUMMARY

The new labeling and the proposed changes are sensible and draw needed attention to the problem of acetaminophen toxicity. To prevent unintentional acetaminophen overdoses, education of patients and health care professionals is urgently needed so that the dangers of consuming excess acetaminophen daily are understood.

■ REFERENCES


ADDRESS: Amy Schilling, PharmD, Department of Pharmacy, JH11-02, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail schilla2@ccf.org.

We Welcome Your Letters

We encourage you to write to us, either to respond to an article published in the Journal or to address a clinical issue of importance to you. You may submit letters by mail, fax, or e-mail.

Mailing address

Letters to the Editor
Cleveland Clinic Journal of Medicine
9500 Euclid Ave., NA32
Cleveland, OH 44195
Fax: 216.444.9385
E-mail: ccjm@ccf.org

Please be sure to include your full address, phone number, fax number, and e-mail address. Please write concisely, as space is limited. Letters may be edited for style and length. We cannot return materials sent. Submission of a letter constitutes permission for the Cleveland Clinic Journal of Medicine to publish it in various editions and forms.

We Welcome Your Letters

We encourage you to write to us, either to respond to an article published in the Journal or to address a clinical issue of importance to you. You may submit letters by mail, fax, or e-mail.

Mailing address

Letters to the Editor
Cleveland Clinic Journal of Medicine
9500 Euclid Ave., NA32
Cleveland, OH 44195
Fax: 216.444.9385
E-mail: ccjm@ccf.org

Please be sure to include your full address, phone number, fax number, and e-mail address. Please write concisely, as space is limited. Letters may be edited for style and length. We cannot return materials sent. Submission of a letter constitutes permission for the Cleveland Clinic Journal of Medicine to publish it in various editions and forms.

We Welcome Your Letters

We encourage you to write to us, either to respond to an article published in the Journal or to address a clinical issue of importance to you. You may submit letters by mail, fax, or e-mail.

Mailing address

Letters to the Editor
Cleveland Clinic Journal of Medicine
9500 Euclid Ave., NA32
Cleveland, OH 44195
Fax: 216.444.9385
E-mail: ccjm@ccf.org

Please be sure to include your full address, phone number, fax number, and e-mail address. Please write concisely, as space is limited. Letters may be edited for style and length. We cannot return materials sent. Submission of a letter constitutes permission for the Cleveland Clinic Journal of Medicine to publish it in various editions and forms.

We Welcome Your Letters

We encourage you to write to us, either to respond to an article published in the Journal or to address a clinical issue of importance to you. You may submit letters by mail, fax, or e-mail.

Mailing address

Letters to the Editor
Cleveland Clinic Journal of Medicine
9500 Euclid Ave., NA32
Cleveland, OH 44195
Fax: 216.444.9385
E-mail: ccjm@ccf.org

Please be sure to include your full address, phone number, fax number, and e-mail address. Please write concisely, as space is limited. Letters may be edited for style and length. We cannot return materials sent. Submission of a letter constitutes permission for the Cleveland Clinic Journal of Medicine to publish it in various editions and forms.